Search company, investor...



Other Investors | Alive

About NeuroKey

NeuroKey A/S develops drugs for the critical care segment addressing the need for emergency medication that can increase the survival rate and reduce the risk of lasting neurological damage in critical care patients.

Headquarters Location

1. Diplomvej




Missing: NeuroKey's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NeuroKey's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest NeuroKey News

Brain-computer interface allowing 'locked-in' ALS patients to communicate earns European approval

Jun 1, 2021

Jun 1, 2021 10:05am Switzerland’s Wyss Center developed the NeuroKey platform to analyze the signals collected by electrodes implanted on the brain and translate them into words and sentences to help nonverbal patients communicate. (Ildar Imashev/Getty Images)(Ildar Imashev / Getty Images) The dream of a device converting nonverbal amyotrophic lateral sclerosis (ALS) patients’ brainwaves into speech could finally become a reality now that a neural signal processing platform designed to do just that has received regulatory clearance in Europe. The NeuroKey platform was developed by the Wyss Center for Bio and Neuroengineering, a nonprofit research institute in Switzerland. Though researchers continue to develop the platform with a goal of one day using brain signals to restore movement and collect health data like body temperature and blood flow, they’ve already received a CE mark for NeuroKey’s ability to enable communication. NeuroKey works by analyzing high-channel-count, high-frequency signals collected by electrodes implanted on the brain and wired to a computer. The platform’s algorithm identifies the intention behind those signals and helps users piece together words and sentences using an automated speller or a simple yes/no prompt. While the software continuously learns and updates itself based on its work translating a user’s brainwaves into words, it also provides audio feedback to users to help make their brain activity more compatible with the NeuroKey algorithms. The platform is designed for home use and was created to be easily launched and calibrated by family members and caregivers. It has already been deployed in the home in a single case study of a patient who is completely locked in—meaning he is unable to speak or move—due to a fast-progressing form of ALS. “We developed NeuroKey because we couldn’t find a software platform that met our needs,” said David Ibáñez Soria, Ph.D., the Wyss Center’s program manager for NeuroKey. He continued, “We needed software that could handle large data streams in real time from hundreds of channels recording from the human brain. We also needed the flexibility to record from various types of electrodes. With our first application now CE marked, we look forward to bringing our solution to more clinical settings.”

NeuroKey Frequently Asked Questions (FAQ)

  • What is NeuroKey's latest funding round?

    NeuroKey's latest funding round is Other Investors.

  • Who are the investors of NeuroKey?

    Investors of NeuroKey include Novo Holdings.

  • Who are NeuroKey's competitors?

    Competitors of NeuroKey include Invistics, Aerogen, Protagonist Therapeutics, Carena, Neuraltus Pharmaceuticals and 11 more.

Compare NeuroKey to Competitors

Wrightwood Technologies

The company are a technology development and licensing firm with a strong focus on robotics and machine intelligence applications and their integration into industries such as pharmaceuticals and health care. The company take great pride in the company's diverse and knowledgeable staff, who make such ventures possible. Wrightwood Technologies Inc. aims to provide both the public and private sectors with technologies and services that improve efficiency, increase production, reduce costs, eliminate waste, and improve societies' over-all quality of life.

NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.


Palkion, Inc. is a private early stage company developing oral drugs to treat anemia based on the discovery and development of compounds that inhibit prolyl hydroxylase enzymes.

Femta Pharmaceuticals

Femta is developing a new generation of antibody therapeutics for major disease indications.

NanoMedex Pharmaceuticals

NanoMedex uses patented formulation strategies to dissolve drugs in water that are only soluble in fats or lipids. Once dissolved in water, these drugs can be administrated intravenously. In hospitals, intravenous administration is preferred by older patients to eliminate swallowing, by physicians to increase certainty that the correct drug dose is given, and by health care providers to ensure that Medicare reimburses 100 percent of costs (versus 50 percent for oral administration).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.